WuHan RedBird Biotech Co,Ltd.

Various top quality steroids, semi-finished oils, SARMs, other pharmaceutical raw materials.

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsPharmaceutical Raw Materials

API Pharmaceutical Raw Materials Fulvestrant Faslodex Breast Cancer Steroids 129453-61-8

Certification
China WuHan RedBird Biotech Co,Ltd. certification
China WuHan RedBird Biotech Co,Ltd. certification
Customer Reviews
Ok thanks. So far everything looks good will be in contact. Once again great business I appreciate it

—— Russell

ja natürlich ist die Qualität gut von euch.ich kaufe ja immer bei euch.

—— Joachim

Thanks my brother it is on the way.. Be here at my house Monday.. Yes .. Good morning to u.. And I'm working to do more soon..!

—— Terry

I'm Online Chat Now

API Pharmaceutical Raw Materials Fulvestrant Faslodex Breast Cancer Steroids 129453-61-8

API Pharmaceutical Raw Materials Fulvestrant Faslodex Breast Cancer Steroids 129453-61-8
API Pharmaceutical Raw Materials Fulvestrant Faslodex Breast Cancer Steroids 129453-61-8 API Pharmaceutical Raw Materials Fulvestrant Faslodex Breast Cancer Steroids 129453-61-8

Large Image :  API Pharmaceutical Raw Materials Fulvestrant Faslodex Breast Cancer Steroids 129453-61-8

Product Details:

Brand Name: Product Name

Payment & Shipping Terms:

Minimum Order Quantity: 100Grams
Price: Negotiated
Packaging Details: Foil Bag
Delivery Time: 3-7days after received payment
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: 5000Kg Per Month
Detailed Product Description
Product Name: Fulvestrant Alias: Faslodex
Appearance: White Powder Assay: 99%
Cas: 129453-61-8 Usage: Breast Cancer Treatment
High Light:

pharma grade steroids

,

pharmaceutical anabolic steroids

API Pharmaceutical Raw Materials Fulvestrant Faslodex Breast Cancer Steroids 129453-61-8

 

Synonyms: Faslodex
CAS:129453-61-8
Molecular Fomular:C32H47F5O3S
Molecular Weight:606.77
Appearance:white powder

Fulvestrant is a highly selective estrogen receptor antagonist. It exerts its action in the body not by
targeting the production of estrogen, but by preventing it from exerting activity on the body. It does this by binding available estrogen receptors in a competitive manner, making them unavailable for circulating
estrogens. This mode of action is very similar to Nolvadex and Clomid, although unlike these two agent
fulvestrant does not have mixed agonist/antagonist properties. It is a pure estrogen receptor antagonist.
This agent also stands out as the first inject able estrogen antagonist to catch the attention of the athletic
and bodybuilding world. Although not widely used here, when applied it may be effective drug for
mitigating the side effects of excess estrogen caused by anabolic/androgenic steroid use such as
gynecomastia, fat buildup, and increased water retention.

Fulvestrant is FDA approved for the treatment of hormone receptor positive metastatic breast cancer in
postmenopausal women with disease progression following anti estrogen therapy. The recommended
dose is 250mg administered intramuscularly per month as a single 5ml injection or two 2.5ml injections.
When used off label to mitigate the estrogenic side effects of anabolic/androgenic steroid use, male
athletes and bodybuilders may find a similar dose as is used for medical reasons to be effective for their
needs.

API Pharmaceutical Raw Materials Fulvestrant Faslodex Breast Cancer Steroids 129453-61-8 0

Quality Test Report(COA):


Test Item

Specification

Results

Appearance

A white to off-white crystalline powder

White crystalline powder

Identification

The retention time of the major peak in the chromatogram of the assay preparation is same as that of the standard preparation obtained in the assay

Conform

Any Individual impurity

Not more than 0.10%

0.18%

Total impurities

Not more than 1.0%

0.44%

Ratio of
isomers

Fulvestran A

50.0%-60.0%

51.70%

Fulvestran B

40.0%-50.0%

47.86%

Purity

99.0%

99.56%
 

 

Applications:


Fulvestrant Acetate is a selective estrogen receptor degrader (SERD). It is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.

Fulvestrant Acetate provides effective second-line therapy in metastatic or locally advanced breast cancer for postmenopausal women who relapse or progress after previous endocrine therapy.

Four clinical trials in this setting showed similar efficacy to the other hormonal agents (aromatase inhibitors and tamoxifen) with good tolerability profile. Fulvestrant had a lower incidence of joint disorders.

A Phase 2 clinical trial, sponsored by Atossa Genetics, is being conducted by Dr. Sheldon Feldman, President of the The American Society of Breast Surgeons, at Columbia University Breast Center in New York City on the use of Fulvestrant Acetate administered through the microcatheter into the lactiferous duct as neoadjuvant treatment forductal carcinoma in situ and invasive breast cancer.

 

Anti-Estrogens


Femara (Letrozole)
Nolvadex (Tamoxifen Citrate)
Arimidex (Anastrozole)
Aromasin (Exemestane)
Clomid (Clomiphene Citrate)
Fareston (Toremifene Citrate)
Evista (Raloxifene Hydrochloride)
Cytadren (Aminoglutethimide)

API Pharmaceutical Raw Materials Fulvestrant Faslodex Breast Cancer Steroids 129453-61-8 1

Fulvestrant/ Faslodex & Breast Cancer:

Fulvestrant (trade name Faslodex) which was developed by AstraZeneca isan intramuscular injection drug, and it was approved for marketing by the US Food and Drug Administration in April 2002.Fulvestrantis a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. Fulvestrant is used to treat hormone receptor positive breast cancer (breast cancer that depends on hormones such as estrogen to grow) in women who have experienced menopause (change of life; end of monthly menstrual periods) and whose breast cancer has worsened after they were treated with antiestrogen medications such as tamoxifen (Nolvadex). Fulvestrant is in a class of medications called estrogen receptor antagonists.

 

Pharmaceutical Raw Material Products:

Adrafinil to increases the brain neurotransmitter, hypocretin
Aniracetam to improve learning and memory, increase perception, reduce anxiety and increase reflexes
Carphedon

anti-amnesic, antidepressant,anticonvulsant, antipsychotic, anxiolytic, andmemory

enhancement effects

Centrophenoxine shown to improve memory, have a mentally stimulating effect, and improve general cognition for elder patients
Coluracetam potential use in prevention and treatment of ischemicretinopathy and retinaland optic nerve injury and a potential therapeutic drug for schizophrenia
IDRA-21 shown to be valuable in memory improvement, cognitive enhancement, stimulation, and reversing cognitive deficits
Modafinil to improve ability to focus in duration and intensity, analytic capabilities, memory recall and rententio, mood and well-being.
Noopept

to offer many benefits in terms of improving memory, learning capacity, focus, and

concentration

NSI-189 to stimulate neurogenesis of human hippocampal stem cells in vitro and in vivo
Oxiracetam

highly effective at increasing attention span, memory, mental energy and cognitive

processing

PRL-8-53 to improve learning and memory
Sunifiram

as an ampakine because it gains its effectiveness through the increasing glycine

receptor binding

Unifiram to improve learning and memory, increase perception, reduce anxiety and increase reflexes
Vinpocetine shown to be valuable in protecting heart, visual, and hearing functions, among other benefits

Contact Details
WuHan RedBird Biotech Co,Ltd.

Contact Person: tommy

Send your inquiry directly to us (0 / 3000)